Volume 6.45 | Nov 27

Prostate Cell News 6.45 November 27, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors
Scientists showed that two classes of luminal progenitors exist within a tumor. Not only did tumors contain previously described multipotent progenitors, but also a major population of committed luminal progenitors. [Cell Rep] Full Article | Graphical Abstract
Cryopreservation Media for Stem Cells - Learn More!
PUBLICATIONS (Ranked by impact factor of the journal)

A PCA3 Gene-Based Transcriptional Amplification System Targeting Primary Prostate Cancer
PCA3-3STA activity was highly specific for prostate cancer (PCa) cells, ranging between 98.7- and 108.0-fold higher than that for benign primary prostate epithelial or non-PCa cells, respectively. [Oncotarget] Full Article

Integrated Network Model Provides New Insights into Castration-Resistant Prostate Cancer
Investigators constructed a comprehensive castration-resistant prostate cancer regulatory network by integrating multiple pathways such as the MEK/ERK and the PI3K/AKT pathways. [Sci Rep] Full Article

Estrogens Down-Regulate the Stem Cell Factor (SCF)/c-KIT System in Prostate Cells: Evidence of Antiproliferative and Proapoptotic Effects
Scientists evaluated the role of 17β-estradiol in regulating the expression of SCF/c-KIT in human prostate cell lines and rat prostate, and investigated the consequent effects on prostate cell proliferation and apoptosis. [Biochem Pharmacol] Abstract

Disulfiram and Its Novel Derivative Sensitize Prostate Cancer Cells to the Growth Regulatory Mechanisms of the Cell by Re-Expressing the Epigenetically Repressed Tumor Suppressor—Estrogen Receptor β
To increase the DNA-methyltransferase (DNMT)-inhibitory activity of disulfiram (DSF), its chemical scaffold was optimized and compound-339 was discovered as a doubly potent DSF-derivative with similar off-target toxicity. It potently and selectively inhibited cell proliferation of prostate cancer cells in comparison to normal cells by promoting cell-cycle arrest and apoptosis, accompanied with inhibition of total DNMT activity, and re-expression of estrogen receptor-β. [Mol Carcinog] Abstract

Pc2-Mediated SUMOylation of WWOX Is Essential for Its Suppression of DU145 Prostate Tumorigenesis
Investigators report that WW domain-containing oxidoreductase (WWOX) is modified by small ubiquitin-like modifier (SUMO) proteins and represses DU145 prostate cancer tumorigenesis in a SUMOylation-dependent manner. [FEBS Lett] Abstract

Long Non-Coding RNA MEG3 Inhibits Cell Proliferation and Induces Apoptosis in Prostate Cancer
Researchers aimed to detect maternally expressed gene 3 (MEG3) expression in clinical prostate cancer tissues, and to investigate its biological functions in the development of prostate cancer and the underlying mechanism. [Cell Physiol Biochem] Full Article

Superoxide Dismutase 1 Regulation of CXCR4-Mediated Signaling in Prostate Cancer Cells is Dependent on Cellular Oxidative State
The authors showed that superoxide dismutase (SOD1) interacts directly with the first intracellular loop of CXCR4 and that the CXCL12/CXCR4-mediated regulation of AKT activation, apoptosis and cell migration in prostate cancer cells is differentially modulated under normal versus hypoxic conditions when SOD1 is present. [Cell Physiol Biochem] Full Article

Mechanisms of Growth Inhibition of Primary Prostate Epithelial Cells following Gamma Irradiation or Photodynamic Therapy Include Senescence, Necrosis, and Autophagy, but not Apoptosis
Scientists investigated the consequences of treating primary prostate epithelial cells with gamma irradiation and photodynamic therapy, both of which act through production of reactive oxygen species. [Cancer Med] Full Article


Does Gleason Score at Initial Diagnosis Predict Efficacy of Abiraterone Acetate Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer? An Analysis of Abiraterone Acetate Phase III Trials
The usefulness of Gleason score at initial diagnosis as a predictive marker of response to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer was explored retrospectively. [Ann Oncol] Abstract

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
Persistent Androgen Receptor Addiction in Castration-Resistant Prostate Cancer
This review will provide an overview of the more clinical relevant pathways that have been implicated in the emergence of drug resistance in men with castration-resistant prostate cancer and highlight some of the ongoing efforts towards developing therapeutics to impair these mechanisms. [J Hematol Oncol] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
ESSA Announces Enrollment of First Patient in Phase I/II Trial
ESSA Pharma Inc. announced that the first patient has been enrolled in ESSA’s Phase I/II clinical study of EPI-506 as a treatment for metastatic castration-resistant prostate cancer. [ESSA Pharma Inc.] Press Release

The US Patent and Trademark Office Issues a Notice of Allowance for New Foxy-5 Patent
WntResearch AB announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new Foxy-5 patent, covering treatment of prostate cancer. [WntResearch AB] Press Release

Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide. [Université de Montréal] Press Release

From our sponsor:
Want to learn more about ALDH in breast cancer treatment response?
Listen to the podcast.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposia – Stem Cells and Cancer
March 6-10, 2016
Breckenridge, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Computational Biologist – Prostate Cancer (Cancer Research UK Manchester Institute)

NEW Statistician/Bioinformatician – Prostate Cancer (Institute of Cancer Research)

Postdoctoral Position – Molecular Cancer Biology (University of Pennsylvania)

Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

Postdoctoral Researcher – Computational Modeling of Prostate Cancer (IBM, Zurich Research Laboratory)

Postdoctoral Position – Androgen Response in Prostate Cancer (University of Victoria)

Group Leader Position – Cancer Research (Oslo University Hospital)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Postdoctoral Position – Cancer Research (University of Texas Health Science Center at Houston)

Postdoctoral Associate – Bioinformatics (Baylor College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us